CYTOMX THERAPEUTICS INC (CTMX) Stock Analyst Ratings
USA - NASDAQ:CTMX - US23284F1057 - Common Stock
3.38 USD
+0.05 (+1.5%)
ChartMill assigns a Buy % Consensus number of 84% to CTMX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.9. This target is 74.6% above the current price.
CTMX was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CTMX.
In the previous month the buy percentage consensus was at a similar level.
CTMX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-21 | Barclays | Maintains | Overweight -> Overweight |
| 2025-09-22 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-07-31 | Oppenheimer | Initiate | Outperform |
| 2025-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-15 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-04-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-01-07 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-09-13 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-06-27 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-28 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-05-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-05-09 | Wedbush | Upgrade | Neutral -> Outperform |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-06 | Jefferies | Upgrade | Hold -> Buy |
| 2024-05-01 | BMO Capital | Reiterate | Market Perform -> Market Perform |
| 2024-04-22 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-03-12 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2024-03-12 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-11-09 | Wedbush | Maintains | Neutral -> Neutral |
| 2023-11-08 | Wedbush | Upgrade | Neutral -> Outperform |
| 2023-08-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2023-03-28 | Mizuho | Maintains | Neutral |
| 2023-01-06 | BMO Capital | Maintains | Market Perform |
| 2022-11-14 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2022-11-10 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2022-07-11 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
CYTOMX THERAPEUTICS INC / CTMX FAQ
Can you provide the average price target for CYTOMX THERAPEUTICS INC stock?
14 analysts have analysed CTMX and the average price target is 5.9 USD. This implies a price increase of 74.6% is expected in the next year compared to the current price of 3.38.
What is the consensus rating for CYTOMX THERAPEUTICS INC (CTMX) stock?
The consensus rating for CYTOMX THERAPEUTICS INC (CTMX) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.